1. Introduction {#sec1-biomolecules-09-00542}
===============

Monosodium glutamate (MSG) is commercially produced as a flavor enhancer in processed foods and home cooking and its use is exponentially increasing worldwide \[[@B1-biomolecules-09-00542]\]. Although the Food and Drug Administration (FDA) have classified MSG as a safe food ingredient \[[@B2-biomolecules-09-00542]\], its safety as a food additive is still debated. For example, cross-sectional and longitudinal studies from our group and others have revealed that the consumption of MSG is associated with human metabolic syndrome \[[@B3-biomolecules-09-00542]\], obesity \[[@B4-biomolecules-09-00542],[@B5-biomolecules-09-00542]\], and arterial hypertension \[[@B6-biomolecules-09-00542]\], although conflicting evidence is also available \[[@B7-biomolecules-09-00542],[@B8-biomolecules-09-00542]\].

The metabolic effects of both oral and parenteral MSG seem to be consistent in animal models, with data available on the effects of MSG on the liver \[[@B9-biomolecules-09-00542],[@B10-biomolecules-09-00542],[@B11-biomolecules-09-00542]\], pancreas \[[@B12-biomolecules-09-00542],[@B13-biomolecules-09-00542]\] and kidney \[[@B9-biomolecules-09-00542],[@B14-biomolecules-09-00542]\]. MSG causes alkaline urine in rats following long-term consumption \[[@B14-biomolecules-09-00542]\]. Urine alkalinization using available alkalinizing agents such as potassium citrate (K citrate) \[[@B15-biomolecules-09-00542],[@B16-biomolecules-09-00542]\] and sodium bicarbonate (NaHCO~3~) \[[@B17-biomolecules-09-00542],[@B18-biomolecules-09-00542]\] is a common treatment for several medical conditions, with the latter used for treating patients who have acute metabolic acidosis or renal proximal tubular acidosis \[[@B19-biomolecules-09-00542]\]. Of importance, potassium citrate has limitations in patients with hyperkalemia \[[@B20-biomolecules-09-00542],[@B21-biomolecules-09-00542],[@B22-biomolecules-09-00542]\] and in long-term supplementation, and NaHCO~3~ may lead to adverse events such as systemic alkalosis \[[@B19-biomolecules-09-00542]\].

Since alkalinizing agents should be used with caution in specific subjects, it is very important to identify whether MSG is also able to alkalinize urine, even though our previous observations revealed that a 9-month exposure to MSG did not affect the blood pH \[[@B14-biomolecules-09-00542]\]. We herein report that oral MSG (resembling human intake) can alkalinize urine within two weeks and our ^1^H-NMR-based metabolomics approach revealed that MSG induced urinary metabolic profiles were similar to those of NaHCO~3~, an alkalinizing agent. We ultimately submit that urinary metabolites may be useful for monitoring dietary consumption, and thus predict MSG effects in human.

2. Materials and Methods {#sec2-biomolecules-09-00542}
========================

2.1. Chemicals and Animals {#sec2dot1-biomolecules-09-00542}
--------------------------

We used 99% pure food-grade MSG (Ajinomoto, Japan), NaCl (RCI Labscan, Thailand), NaHCO~3~ (BDH, Visalia, CA, USA) and 40 6-week old male Wistar rats (approximately 200 g) obtained from the National Laboratory Animal Center (Salaya, Mahidol University, Bangkok, Thailand). Animals were housed for 2 weeks in the Northeast Laboratory Animal Center and maintained under standard conditions (temperature: 23 ± 2 °C, humidity (RH): 30--60%, brightness: 350--400 Lux and 12 h/12 h dark/light cycle) with standard rat chow pellets (Perfect Companion Group, Bangkok, Thailand). All experiments were performed in accordance with the guidelines of KKU animal ethics (AEKKU-NELAC 5/2558).

2.2. Experimental Design {#sec2dot2-biomolecules-09-00542}
------------------------

Rats were assigned into 4 groups, (1) receiving drinking water, (2) receiving water with 1 g% MSG added, (3) receiving water with 0.34 g% NaCl added, which equivalent to the sodium in group 2, and (4) receiving water with 2.4 g% NaHCO~3~ as a positive control for the alkalinizing agent treated group ([Figure 1](#biomolecules-09-00542-f001){ref-type="fig"}). Animals were allowed to access water and food ad libitum and daily water intake was recorded weekly. Food intake (g/day) was measured every 2 weeks. Rats were housed in individual stainless steel metabolic cages for urine sample collection. Urinary samples (24-h urine) were collected one day before (D1) and 14 days after the experiment (D14) and kept at −80 °C until analyzed. At the end of the experiment (D14), all animals were sacrificed using carbon dioxide after 12-h fasting. Kidneys were dissected, washed with normal saline, and divided into cortex and medulla layer, then transferred to cryotubes with TRIzol^®^ Reagent (Invitrogen, Waltham, MA, USA), dipped in liquid nitrogen and stored at −80 °C for gene expression analysis.

2.3. Urine Analysis {#sec2dot3-biomolecules-09-00542}
-------------------

The 24 h urine was thawed at room temperature and analyzed for urine pH and urine electrolyte (sodium, potassium, chloride and bicarbonate). All samples were analyzed at the laboratory services in Srinagarind Hospital, Khon Kaen University and using automatic machine under standard protocol.

2.4. Sample Preparation for ^1^H-NMR Spectroscopic Analysis {#sec2dot4-biomolecules-09-00542}
-----------------------------------------------------------

Urine samples were thawed at room temperature and centrifuged at 18,000× *g*, 4 °C, for 10 min. Then 100 µL of the urine supernatant was transferred to a new tube and mixed with 300 µL of deuterium oxide (D~2~O) (Sigma Aldrich, Gillingham Dorset, UK) and 250 µL of 0.2 M sodium phosphate buffer containing 0.1% sodium trimethylsilyl-\[2,2,3,3-^2^H~4~\]-propionate (TSP), 100% D~2~O and 3 mM sodium azide. The sample was vortexed briefly, and then 600 µL of the mixture was transferred to NMR glass tubes (Wilmad-labglass, Vineland, NJ, USA) with an outer diameter of 5 mm pending NMR analysis.

2.5. ^1^H-Nuclear Magnetic Resonance Spectroscopic Analysis of Urine {#sec2dot5-biomolecules-09-00542}
--------------------------------------------------------------------

Urinary samples were analyzed using a Bruker 600 MHz spectrometer (Bruker Avance III, Bruker Biospin, Rheinstetten, Germany) at a ^1^H frequency of 600.13 MHz with a temperature of 300 K. A standard one-dimensional (1-D) NMR pulse sequence (recycle delay \[RD\]-90°-t~1~-90°-t~m~-90°-acquire free induction decay) was used t~1~ was fixed to 3 µs. The suppression of the water peak was achieved by selective irradiation during recycle delay of 2 s and mixing time (t~m~) of 100 ms. The 90 degree-pulse was adjusted to approximately 10 µs. A total of 128 scans were recorded into 64 K data points with a spectral width of 20 ppm \[[@B23-biomolecules-09-00542]\].

2.6. Data Pre-Processing and Multivariate Statistical Analysis {#sec2dot6-biomolecules-09-00542}
--------------------------------------------------------------

The urinary spectra were calibrated to the TSP peak (δ^1^H 0.00), phased and baseline corrected using TopSpin 3.0 (Bruker, Rheinstetten, Germany). The pre-processed spectra were imported into MATLAB software (MathWorks, R2014a, Natrick, MA, USA) and digitized with a resolution of 0.0005 ppm. Spectral regions containing the TSP peak (δ^1^H −1.00--0.005), water (δ^1^H 4.70--4.90) and urea (δ^1^H 5.71--6.00) were removed. Normalization using the probabilistic quotient method \[[@B24-biomolecules-09-00542]\] and peak alignment using recursive segment-wise peak alignment (RSPA) \[[@B25-biomolecules-09-00542]\] were applied to the remaining spectral data. Unsupervised principal component analysis (PCA) with unit variance (UV) scaling method was initially performed in order to identify any obvious clustering or outliers to unassigned treatment groups. The orthogonal-signal correction-projection to latent structures-discriminant analysis (O-PLS-DA) was then used to investigate the metabolic difference between the control and MSG groups. The O-PLS-DA models are evaluated by the R^2^X and Q^2^Y values, representing the fitness and predictivity of the model, respectively. A two-tailed heteroscedastic *t-test* with Benjamini-Hochberg correction was also used to determine the statistical significance of differences between the groups. Statistical Total Correlation Spectroscopy (STOCSY), the Human Metabolome Database (HMDB version 3.6, Edmonton, AB, Canada) \[[@B26-biomolecules-09-00542],[@B27-biomolecules-09-00542]\] and in-house chemical shift databases were used for metabolite identification.

2.7. Gene Expression Analysis {#sec2dot7-biomolecules-09-00542}
-----------------------------

Total RNAs were extracted from cortex and medulla layers of kidney using TRIzol^®^ reagent method. Tissues weighing about 50--100 mg were preserved in TRIzol^®^ and incubated at room temperature (RT) for 3 min, 200 µL of chloroform was added the mixture was shaken vigorously and incubated at RT for 3 min. The reaction was then centrifuged at 12,000× *g* for 15 min at 4 °C. The upper aqueous phase (60%) was transferred to a new 1.5 mL sterile tube, 500 μL of isopropanol was added, mixed well, and then incubated at RT for 10 min and centrifuged at 12,000× *g* for 10 min at 4 °C. The supernatant was discarded while the pellet was washed by 70% ethanol and centrifuged at 7500× *g* for 5 min at 4 °C (twice). The pellet was air dried at RT, re-suspended in 30--50 μL of DEPC water and then the pellet was dissolved by keeping it at 55 °C for 15 min. Total RNA were stored at −80 °C until used.

RNA concentration was measured with OD at 260 nm and reverse-transcribed to complementary DNA (cDNA) using the high capacity reverse transcription Kit (Applied Biosystem, Foster, CA, USA). Obtained cDNA was diluted to 20 ng/μL and stored at −20 °C until used. Gene expression analysis was determined by real-time PCR, using beta-actin (ACTB) as the internal control for normalization \[[@B28-biomolecules-09-00542]\], in LightCycler^®^ 480 real-time PCR system (Roche Applied Science, Mannheim, Germany). Each PCR condition containing 2.5 μM of primers (forward and reverse primers), cDNA 50 ng/μL, and 2X LightCycler^®^ 480 SYBR green I master mix. The amplification was initiated by pre-incubation at 95 °C for 10 min, followed by 40 cycles at 94 °C for 30 s, 60 °C for 30 s, 72 °C for 1 min, and 79 °C for 0.1 s. Each sample was prepared in duplicate sample and the crossing point (Cp) cycle was calculated and presented as mean ± SEM values. The gene expression levels were determined and the 2^−∆cp^ value; Δcp = Cp~target~ − Cp~actin~ was calculated. Primers for all genes were designed using NCBI with a least one exon-exon junction in the target ([Table 1](#biomolecules-09-00542-t001){ref-type="table"}).

2.8. Statistical Analysis {#sec2dot8-biomolecules-09-00542}
-------------------------

The statistical analysis of the urinary analysis and gene expression were reported as mean ± SEM per group of animals and the differences between groups was compared for statistical significance by Student's t-test. Moreover, all comparisons of gene expression with *p*-values \< 0.05 were considered as statistically significant.

3. Results {#sec3-biomolecules-09-00542}
==========

3.1. MSG Exhibits Urine Chemistries Similar to Alkaline Loading {#sec3dot1-biomolecules-09-00542}
---------------------------------------------------------------

After two weeks, urine analyses indicated that the MSG and NaHCO~3~ treatment groups had significantly higher urine pH compared to controls (pH = 7.82, pH = 9.13, and pH = 6.86, respectively; \*\*\* *p* \< 0.001 for both groups vs. controls), whereas no significant difference in urinary pH was observed between NaCl-treated rats (pH = 6.93) and controls ([Figure 2](#biomolecules-09-00542-f002){ref-type="fig"}A). Urinary Na^+^ was significantly higher in MSG, NaCl, and NaHCO~3~-treated rats compared to controls (3.1 ± 0.17, 4.59 ± 0.31, 8.84 ± 1.12, 1.28 ± 0.05 mEq/day, respectively). Urinary K^+^ excretion in MSG group (1.83 ± 0.06 mEq/day) was significantly higher, whereas the NaHCO~3~-treated group (1.04 ± 0.12 mEq/day) was the opposite to controls (1.50 ± 0.10 mEq/day). Significantly higher levels of HCO~3~^−^ were also revealed in MSG (0.95 ± 0.16 mEq/day) and NaHCO~3-~treated rats (1.14 ± 0.20 mEq/day) but not in NaCl-treated rats (0.20 ± 0.06 mEq/day) compared to controls (0.19 ± 0.02 mEq/day). No significant differences in urinary Cl^-^ were observed between MSG (3.70 ± 0.26 mEq/day) and NaCl-treated rats (3.85 ± 0.31 mEq/day), whereas significantly lower levels were found in NaHCO~3~-treated rats (1.88 ± 0.20 mEq/day) compared to control rats (4.32 ± 0.28 mEq/day) ([Figure 2](#biomolecules-09-00542-f002){ref-type="fig"}B).

3.2. MSG Suppresses HCO~3~^−^ Reabsorption Similar to Alkaline Loading {#sec3dot2-biomolecules-09-00542}
----------------------------------------------------------------------

We used RT-PCR to analyze the expression of the 11 ion-exchanger genes that contribute to the acid-base regulation in the kidney cortex, including the expression of genes related to glutamine/glutamate metabolism and the TCA cycle ([Table 1](#biomolecules-09-00542-t001){ref-type="table"}). Three important ion-exchanger genes involved in HCO~3~^−^ reabsorption (*CAII, NBC1* and *AE1*) were suppressed in MSG-treated rats (1.62 ± 0.456, 0.16 ± 0.065, 0.01 ± 0.002, respectively), similar to that of the NaHCO~3~ group (1.02 ± 0.125, 0.20 ± 0.034, 0.02 ± 0.001, respectively) when compared to controls (4.30 ± 0.865, 0.57 ± 0.127, 0.10 ± 0.041, respectively) ([Figure 3](#biomolecules-09-00542-f003){ref-type="fig"}). No significant differences were observed for *CAII, NBC1,* and *AE1* mRNA expression levels in NaCl-treated rats compared to controls. Glutamine/glutamate metabolism and TCA cycle gene expression in kidney were unchanged in MSG, NaCl and NaHCO~3~ compared to control groups (data shown in [Supplementary Materials](#app1-biomolecules-09-00542){ref-type="app"}).

3.3. MSG Shares Common Urinary Metabolic Profile Resembling Alkaline Loading {#sec3dot3-biomolecules-09-00542}
----------------------------------------------------------------------------

^1^H-NMR spectra of 24 h urine samples from control, MSG, NaCl and NaHCO~3~-treatment groups at day 14 (D14) are plotted in [Figure 4](#biomolecules-09-00542-f004){ref-type="fig"}. Differences in raw spectra between 4.5 ppm and 5.25 ppm were observed in MSG and NaHCO~3~-treated rats compared to NaCl and control rats ([Figure 4](#biomolecules-09-00542-f004){ref-type="fig"}). Urinary NMR spectral data was analyzed using PCA and the scores plot is shown in [Figure 5](#biomolecules-09-00542-f005){ref-type="fig"}. No clustering based on the treatment group was observed in the PCA scores plot ([Figure 5](#biomolecules-09-00542-f005){ref-type="fig"}A). However, the O-PLS-DA cross-validated scores plot shows a clear separation between controls and MSG at D14 ([Figure 5](#biomolecules-09-00542-f005){ref-type="fig"}B) with a permutation p-value of 0.001, R^2^X of 44%, and Q^2^Y of 0.75. Based on PCA and O-PLS-DA, no clustering or separation was observed between controls and the NaCl-treated group ([Figure 5](#biomolecules-09-00542-f005){ref-type="fig"}C,D). In contrast, clear clustering and complete separation were observed based on PCA and O-PLS-DA, between controls and the NaHCO~3~-treated group ([Figure 5](#biomolecules-09-00542-f005){ref-type="fig"}E,F) with a permutation p value of 0.001, R^2^X of 47%, and Q^2^Y of 0.95.

The detected urinary metabolite changes are summarized in [Table 2](#biomolecules-09-00542-t002){ref-type="table"} and changes in the urinary profiles were observed in MSG and NaHCO~3~-treated rats when compared with control animals. In particular, nine urinary metabolites, including glutamate, citrate, malonate, alpha-ketoglutarate, beta-hydroxyisovalerate, 5-aminovalerate, 5-hydroxymethyl-4-methyluracil, dimethylamine, and methylamine were significantly higher in the MSG treatment group, whereas taurine was significantly higher in control animals. Seven urinary metabolites, including glutamate, citrate, malonate, alpha-ketoglutarate, 5-aminovalerate, beta-hydroxyisovalerate, and taurine found in the MSG group were also observed in theNaHCO~3~ group. However, three metabolites, i.e., 3-carboxy-2-methyl-3-oxopropanamine, succinate, and choline were significantly higher in the NaHCO~3~ group compared to controls. The 5-hydroxymethyl-4-methyluracil metabolite was significantly altered in both MSG and NaHCO~3~, but in opposite ways. The similar effects of MSG and NaHCO~3~ supplementation on urine pH, urine electrolytes, ion exchanger gene expression and urinary metabolic markers are illustrated in [Table 3](#biomolecules-09-00542-t003){ref-type="table"}.

4. Discussion {#sec4-biomolecules-09-00542}
=============

The kidney plays a dominant role in maintaining the homeostasis of plasma and urine pH by acid excretion and HCO~3~^−^ reabsorption via ion exchangers. We report for the first time that short-term MSG consumption can induce alkaline urine similar to the NaHCO~3~ supplementation group, and the MSG group has a similar metabolic profile with potentially similar clinical consequences.

First, we believe that the increased urinary pH in the MSG group is secondary to its glutamate composition, not to sodium itself. This is supported by the urinary pH of the NaCl group which does not increase as the amount of Na intake increased compared to the MSG group ([Figure 2](#biomolecules-09-00542-f002){ref-type="fig"}B). Our investigation of MSG-induced alkaline urine confirms previous data from rats receiving 20% dietary MSG for 5 weeks \[[@B29-biomolecules-09-00542]\], fed 6% MSG for 3 months \[[@B30-biomolecules-09-00542]\], or receiving 2 mg/g body weight MSG/day in drinking water for 9 months \[[@B14-biomolecules-09-00542]\]. We also demonstrated that the MSG-treated group has similar urine electrolyte levels when compared to the NaHCO~3-~treated group. MSG-treated rats have significantly higher urinary Na^+^, K^+^ and HCO~3~^−^, as observed with longer supplementation \[[@B14-biomolecules-09-00542]\]. The excretion of Na^+^, K^+^ and HCO~3~^−^ in MSG-treated rats may suggest these elements are excessively uptaken or overproduced by metabolic pathways. Our current hypothesis is that the excess of Na^+^ derives directly from the overconsumption of MSG as show in the NaCl group, whereas HCO~3~^−^ and K^+^ derive from the catabolism of glutamate and other nutrient metabolism. The byproduct of glutamate metabolism might be similar to that of potassium citrate that generates HCO~3~^−^ via its catabolic citric acid cycle, leading to the alkaline urinary pH \[[@B31-biomolecules-09-00542]\]. Alkaline urine may influence the kidney's capacity to secrete or reabsorb metabolites leading to the suppression of bicarbonate reabsorption in the kidney.

Second, the expression of ion exchangers involved in bicarbonate reabsorption in the kidney cortex of MSG-treated rats is decreased ([Figure 3](#biomolecules-09-00542-f003){ref-type="fig"}) and this indicates lower bicarbonate reabsorption in MSG-treated rats, similar to that of the NaHCO~3~ supplemented group, which was not observed in NaCl-treated animals. The decreased NBC1 expression in the proximal tubule has been reported in rats treated with NaHCO~3~ loading \[[@B32-biomolecules-09-00542]\] while the immunostaining intensity of AE1 was increased in metabolic acidosis and reduced in metabolic alkalosis \[[@B33-biomolecules-09-00542]\].

Third, the ^1^H-NMR-based metabolomics approach revealed that the MSG-induced urinary metabolic profiles were similar to the NaHCO~3~ group. In particular, MSG consumption generates a pattern of metabolites with higher levels of glutamate, alpha-ketoglutarate, malonate, citrate, beta-hydroxyisovalerate and 5-aminovalerate, whereas the level of taurine is lower than rats receiving normal drinking water, as also observed in rats receiving NaHCO~3~. A quick observation of the four treatment groups showed differences in the raw spectra between 4.5 ppm and 5.25 ppm in MSG and NaHCO~3-~treated rats compared to NaCl and control rats ([Figure 4](#biomolecules-09-00542-f004){ref-type="fig"}). In agreement with these raw spectra, data analysis using PCA and O-PLS-DA revealed that both MSG and NaHCO~3~ treatments show a clustering difference between treatment and control rats ([Figure 5](#biomolecules-09-00542-f005){ref-type="fig"}).

Ten metabolites that relate to MSG consumption are linked to catabolism of amino acids, fatty acids, vitamin, pyrimidine and citric acid cycle. For example, alpha-ketoglutarate and citrate are intermediates of the citric acid cycle. Alpha-ketoglutarate and glutamate are from transamination reactions. Beta-hydroxyisovalerate and 5-aminovalerate are leucine and lysine degradation products, respectively. Malonate is from either aspartate or fatty acid catabolism. Taurine is from cysteine or serine metabolism whereas dimethylamine and methylamine are from choline metabolism. Lastly, 5-hydroxymethyl-4-methyluracil, a marker of DNA damage, is from pyrimidine catabolism \[[@B34-biomolecules-09-00542]\].

The characterization of the 10 metabolites observed in the MSG treatment group and the 11 metabolites in the NaHCO~3~ treatment group, with some shared changes ([Table 2](#biomolecules-09-00542-t002){ref-type="table"}), warrants a more detailed discussion. The higher levels of amino acid (glutamate) and amino acids-related metabolites (alpha-ketoglutarate, malonate, citrate, beta-hydroxyisovalerate and 5-aminovalerate) found in the urine of MSG and NaHCO~3~-treated groups compared to controls may be related to their urine alkalinizing condition. Glutamate kidney re-uptake requires glutamate transporters \[[@B35-biomolecules-09-00542]\], which co-transport H^+^ with glutamate, and high urinary pH may inhibit glutamate re-uptake in the renal brush border, thus contributing to the higher urinary glutamate. Alkaline urine also inhibits metabolite reabsorption in the case of alpha-ketoglutarate, malonate and citrate in the MSG and NaHCO~3~-treated rats. Based on their pKa, the alkaline urine may deprotonate alpha-ketoglutarate^1-^, malonate^1−^, and citrate^2−^ to form alpha-ketoglutarate^2−^, malonate^2−^, and citrate^3−^, respectively, and affect their reabsorption \[[@B36-biomolecules-09-00542],[@B37-biomolecules-09-00542]\]. In metabolic/respiratory alkalosis, alpha-ketoglutarate excretion increases to levels that are several times above normal \[[@B38-biomolecules-09-00542],[@B39-biomolecules-09-00542],[@B40-biomolecules-09-00542]\]. Under alkaline loading conditions, the blood concentration of alpha-ketoglutarate rises and net alpha-ketoglutarate reabsorption in the proximal tubule and Henle's loop is decreased, making the alpha-ketoglutarate secretion increase in the same nephron segments, and leading to a significant increase in the urinary excretion of alpha-ketoglutarate \[[@B41-biomolecules-09-00542],[@B42-biomolecules-09-00542]\]. Moreover, citrate, alpha-ketoglutarate, and succinate competitively inhibit the transport of each other \[[@B43-biomolecules-09-00542]\].

A similar scenario is also hypothesized for malonate as citrate and malonate compete for reabsorption in the renal tubular cell \[[@B44-biomolecules-09-00542]\]. The higher level of a lysine degradation product, 5-aminovalerate and leucine degradation product, beta-hydroxyisovalerate found in MSG and NaHCO~3~ supplemented animals may relate to tissue injury. The beta-hydroxyisovalerate itself is a metabotoxin \[[@B45-biomolecules-09-00542]\]. Taurine is a normal constituent of human urine, however, its level varies markedly among individuals depending on age, hormones, stress, and diet \[[@B46-biomolecules-09-00542]\], however, our control and MSG, NaHCO~3~ groups had comparable characteristics, except for MSG and NaHCO~3~ intake. The decrease in taurine in the MSG and NaHCO~3~ groups may relate to either taurine use, secondary to oxidative stress, or to its degradation, as observed in chronic renal failure \[[@B47-biomolecules-09-00542]\], glomerulonephritis, diabetic nephropathy, chronic renal failure, and acute kidney injury \[[@B48-biomolecules-09-00542]\].

In fact, excessive renal metabolism of glutamate can be a source of ROS. Moreover, chronic MSG intake is associated with decreased levels of antioxidant enzymes and increased lipid peroxidation; leading to cellular and functional damage of the kidneys \[[@B49-biomolecules-09-00542]\]. Such effects are not observed with sodium bicarbonate (NaHCO~3~). The distinct urinary metabolites between MSG and NaHCO~3~ are methylamine and dimethylamine, which were only observed in MSG-treated animals. Methylamine and dimethylamine are metabolites from the gut microbiota \[[@B50-biomolecules-09-00542],[@B51-biomolecules-09-00542]\]. This gut microbiota is also found in human intestine \[[@B52-biomolecules-09-00542]\]. MSG may alter the gut microbiota community, specifically those that are involved in methylamine metabolism. However, the connection of MSG consumption and methylamine metabolism needs to be further explored.

In summary, MSG consumption may resemble alkali loading ([Table 3](#biomolecules-09-00542-t003){ref-type="table"}), causing suppression of ion exchangers responsible for bicarbonate absorption which correspond to the higher excretion of urinary bicarbonate in MSG and NaHCO~3~-treated rats. MSG consumption exhibits similar features to alkaline loading, causing alkaline urine, leading to alteration of di- and tricarboxylic metabolites, i.e., glutamate, alpha-ketoglutarate, citrate, and malonate reabsorption in the kidney. We may also speculate that MSG itself may alter the gut microbiome to catabolize dietary molecules, such as amino acids and choline and urinary metabolites could be potential markers for MSG consumption in animals and should now be studied in humans. However, there are two limitations in this present study to be aware of: the effects of MSG consumption were only tested in male animals, and the frequency of obtaining MSG was every time the animals drunk water. This behavior differs from humans because humans receiving MSG only consume MSG at their regular meal times, which is usually 2-3 times a day.

5. Conclusions {#sec5-biomolecules-09-00542}
==============

Short-term MSG consumption exhibits similar effects as consuming NaHCO~3~, an alkalinizing agent; it induces alkaline urine and alters the ion-exchanger gene expression that relates to bicarbonate kidney reabsorption. This implies that MSG consumption induces metabolic changes with a pattern of urinary metabolites, which may be used for monitoring MSG exposure in humans.
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![A schematic diagram showing the experimental design and sample collection.](biomolecules-09-00542-g001){#biomolecules-09-00542-f001}

![Urine pH (**A**) and electrolytes (**B**) after treatment in male Wistar rats supplemented with 1 g% MSG, 0.34 g% NaCl and 2.4 g% NaHCO~3~ (*n* = 10 per group). Data are shown as mean ± SEM and *p*-values calculated by Student's *t-test* (\* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.001).](biomolecules-09-00542-g002){#biomolecules-09-00542-f002}

![Changes in mRNA expression of ion exchanger genes in cortex layers of rat kidney after 14 days of MSG (*n* = 10), NaCl (*n* = 10) and NaHCO~3~ (*n* = 10) supplementation compared to controls (*n* = 8) (**A**) *CAII*, (**B**) *NBC1*, (**C**) *AE1*. Data are shown as mean ± SEM relative gene expression with beta-actin, \* *p* \< 0.05; \*\* *p* \< 0.01; \*\*\* *p* \< 0.001. Abbreviations: *CAII*: carbonic anhydrase2, *NBC1*: Na^+^-HCO~3~^−^ co-transporter1; *AE1*: anion exchanger1.](biomolecules-09-00542-g003){#biomolecules-09-00542-f003}

![The 600 MHz ^1^H-NMR spectra of urinary samples collected over 24 h at day 14 from (**A**) control, (**B**) MSG-fed, (**C**) NaCl-fed, and (**D**) NaHCO~3~ --fed rats (*n* = 10 per group).](biomolecules-09-00542-g004){#biomolecules-09-00542-f004}

![PCA scores plots (left panel) and O-PLS-DA cross-validated scores plots (right panel) of 24-h urine at day 14 (U24 D14). (**A**,**B**): control (blue) vs. MSG (red); (**C**,**D**): control (blue) vs. NaCl (green); (**E**,**F**): control (blue) vs. NaHCO~3~ (brown) (*n* = 10 per group).](biomolecules-09-00542-g005){#biomolecules-09-00542-f005}
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Oligonucleotide primers used for gene expression analysis.

  Group                                Gene                       Primer                     Oligonucleotide Sequence   Product Size (bp)
  ------------------------------------ -------------------------- -------------------------- -------------------------- -------------------
  Internal Control                     *Beta-actin*               Forward                    ACAACCTTCTTGCAGCTCCT       197
  Reverse                              ACCCATACCCACCATCACAC                                                             
  Ion-Exchanger                        *AE1*                      Forward                    TCCCGCTACACTCAGGAGAT       118
  Reverse                              CAGGGGCATAGCTCTCTTGT                                                             
  *CAII*                               Forward                    TGCTGGAATGTGTGACCTGG       101                        
  Reverse                              CTCCCCCTCCGAATTGAAGT                                                             
  *Na^+^/K^+^ ATPase*                  Forward                    CAGCACTCGCTTTCCCTCG        189                        
  Reverse                              GGCCAGGCAGCCATAGAATA                                                             
  *H^+^/K^+^ ATPase*                   Forward                    CCCCTGAGTACGTGAAGTTCG      168                        
  Reverse                              CCACAACCACAGCAATGAGTG                                                            
  *CA IV*                              Forward                    GTCTATGCCCTCAAGCACCA       114                        
  Reverse                              TTGGGCTCCTTGGCTTGAAT                                                             
  *NBC1*                               Forward                    GCTATCCCGGCTTTGCTAGT       153                        
  Reverse                              GAAGGAGCACACCACCATGA                                                             
  *NHE3*                               Forward                    ACTGCTTAATGACGCGGTGA       160                        
  Reverse                              GAAGGCGAAGATGACACCA                                                              
  *Rhbg*                               Forward                    TGTCCGCTACAACCACGAAA       96                         
  Reverse                              TGGAAGCTTGGGTAGCGAAA                                                             
  *Rhcg*                               Forward                    CTCTTCGGCGTGTTCGTGC        200                        
  Reverse                              CCTACAGCGCTGAACCCATA                                                             
  *Pendrin*                            Forward                    AGAACCAGGCCAAATCCAGG       83                         
  Reverse                              CAAGTCTACGCATGGCCTCA                                                             
  *H^+^-ATPase*                        Forward                    TGCCTTCAGTTAGAGAGGCCGTGA   147                        
  Reverse                              TGCCAAGAAGAGTCTGGGACAAGG                                                         
  Glutamate and Glutamine Metabolism   *XC-sys*                   Forward                    GCATCGTCCTTTCAAGGTGC       150
  Reverse                              AAGAGGTAATACGCCGGGAC                                                             
  *EAAC1*                              Forward                    AAACCACGGTGCTCGGTC         127                        
  Reverse                              ACCGGCGTTTGTGAGGAATC                                                             
  *Glutaminase*                        Forward                    TGGGCATGATGTGTTGGTCT       199                        
  Reverse                              TACGCAGCAAACAGGAGGTT                                                             
  *SNAT3*                              Forward                    GGAACGGAGTGCTGAACGTG       83                         
  Reverse                              CTGAAACCACCCCAGAGCAC                                                             
  *PEPCK*                              Forward                    TGCCATGGCTGCTATGTACC       89                         
  Reverse                              TTTGGATGCTACGGCATGGT                                                             
  TCA Cycle                            *Citrate synthase*         Forward                    TGCTACACAGAACCTCAGTTCAC    243
  Reverse                              ATCTGACACGTCTTTGCCGA                                                             
  *Aconitase*                          Forward                    CCTGTACCTGACACTGCTCG       223                        
  Reverse                              TGTAGTCAGAGGGGTCAGCA                                                             
  *IDH*                                Forward                    TGCAAAAATATCCCCCGCCT       144                        
  Reverse                              GCCATCCTTTGGGGTGAAGA                                                             

Abbreviations: *AE1*: anion exchanger1, *CAII*: carbonic anhydrase2, *CAIV*: carbonic anhydrase4, *NBC1*: Na^+^-HCO~3~^−^ co-transporter1, *NHE3*: Na^+^/H^+^ exchanger3, *Rhbg:* Rh family B glycoprotein, *Rhcg*: Rh family C glycoprotein, *XC-sys*: Cysteine/glutamate transporter, *EAAC1*: Excitatory amino acid transporter1, *SNAT3*: Na^+^-coupled neutral amino acid transporter3, *PEPCK*: Phosphoenolpyruvate carboxykinase, *IDH*: Isocitrate dehydrogenase.
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###### 

Relative changes at 2 weeks of 24 h urine metabolites in control, MSG and NaHCO~3~ rats (*n* = 10 per group) using the ^1^H-NMR profiles.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Metabolites                           Chemical Shift (Multiplicity)                         MSG and NaHCO~3~ Induced Metabolic Changes Compared to Control   The Acid Dissociation Constant (pKa)   
  ------------------------------------- ----------------------------------------------------- ---------------------------------------------------------------- -------------------------------------- ---------------------------------------------
  3-carboxy-2-methyl-3-oxopropanamine   **1.08 (d);** 2.49 (m); 3.19(m); 3.56 (m); 3.72 (m)   \-                                                               (\*0.95)(∆3.33 × 10^−10^)              

  Beta-hydroxyisovalerate               1.28 (s)                                              (\*0.77)(∆6.19 × 10^−5^)                                         (\*0.89)(∆1.83 × 10^−7^)               pKa~1~ = 4.55

  5-aminovalerate                       1.68 (m); **2.21 (t);** 3.02 (t)                      (\*0.79)(∆3.35 × 10^−5^)                                         (\*0.95)(∆1.38 × 10^−10^)              pKa~1~ = 4.27, pKa~2~ = 10.77

  5-hydroxymethyl-4-methyluracil        **1.98 (s);** 4.42 (s)                                (\*0.83)(∆5.84 × 10^−6^)                                         (\*−0.84)(∆4.15 × 10^−6^)              pKa~1~ = 9.87

  Glutamate                             **2.02 (m);** 2.34 (m); 3.76 (m)                      (\*0.85)(∆2.31 × 10^−6^)                                         (\*0.88)(∆2.91 × 10^−7^)               pKa~1~ = 2.19, pKa~2~ = 4.25, pKa~3~ = 9.67

  Succinate                             2.41 (s)                                              \-                                                               (\*0.87)(∆8.10 × 10^−7^)               pKa~1~ = 4.16, pKa~2~ = 5.61

  Alpha-ketoglutarate                   **2.44 (t);** 3.01 (t)                                (\*0.75)(∆1.37 × 10^−4^)                                         (\*0.89)(∆1.46 × 10^−7^)               pKa~1~ = 2.47, pKa~2~ = 4.68

  Citrate                               **2.54 (d);** 2.66 (d)                                (\*0.87)(∆5.10 × 10^−7^)                                         (\*0.96)(∆4.63 × 10^−11^)              pKa~1~ = 3.14, pKa~2~ = 4.77, pKa~3~ = 6.39

  Methylamine                           2.61 (s)                                              (\*0.52) (∆0.019)                                                \-                                     pKa~1~ = 10.63

  Dimethylamine                         2.77 (s)                                              (\*0.71)(∆4.76 × 10^−4^)                                         \-                                     pKa~1~ = 2.36, pKa~2~ = 10.21\

  Malonate                              3.11 (s)                                              (\*0.74)(∆2.17 × 10^−4^)                                         (\*0.97)(∆1.66 × 10^−12^)              pKa~1~ = 2.85, pKa~2~ = 5.70

  Choline                               **3.21 (s);** 3.52 (m); 4.07 (m)                      \-                                                               (\*0.80)(∆2.70 × 10^−5^)               pKa~1~ = 13.9

  Taurine                               **3.25 (t);** 3.43 (t)                                (\*−0.73)(∆2.69 × 10^−4^)                                        (\*−0.80)(∆2.80 × 10^−5^)              pKa~1~ = 1.15, pKa~2~ = 9.06
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

R2X and Q2Y show the variance explained and predicted by each model while *P* values for all models were derived from the permutation test (*n* = 1000). (+) indicates a higher correlation, whereas (−) indicates a lower correlation of urinary metabolite after MSG and NaHCO~3~ consumption. (\*) represents the correlation value and (∆) represents the *p* value of the specific peak. The bolded chemical shift per metabolite was used as the STOCSY driver peak and for deriving the correlation and *p*-value. (\* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.001*).* Abbreviations: s, singlet; d, doublet; t, triplet; m, multiplet, pKa; acid dissociation constant. Note; (−) Control vs. (+) NaCl, R2X = 38%, Q2Y = 0.12, *p* = 0.433.
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###### 

The similar effects of MSG and NaHCO~3~ supplementation on urine pH, urine electrolytes, ion exchanger gene expression and urinary metabolic markers.

  -------------------------------------------------------------------------------
                                                Control   MSG   NaCl   NaHCO~3~
  --------------------------------------------- --------- ----- ------ ----------
  Urine pH                                      \-        ↑     \-     ↑

  Urine Electrolytes (HCO~3~^−^)                \-        ↑     \-     ↑

  Ion exchanger gene expression\                \-        ↓     \-     ↓
  (HCO~3~^−^ reabsorption, *CAII, NBC1, AE1*)                          

      Urinary metabolic markers\                \-        ↑     \-     ↑
        Beta-hydroxyisovalerate\                                       
        5-aminovalerate\                                               
        Glutamate\                                                     
        Alpha-ketoglutarate\                                           
        Citrate\                                                       
        Malonate                                                       

  Taurine                                       \-        ↓     \-     ↓
  -------------------------------------------------------------------------------
